Tilray | TRLY - Sales Revenues


Tilray reported $217.51M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acasti Pharma USD -4.76M 4.76M Dec/2024
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Aurora Cannabis CAD 38.01M 56.18M Mar/2026
Avita Medical AUD 17.61M 805K Dec/2025
Canopy Growth CAD 71.25M 3.29M Mar/2026
Cronos Group USD 53.01M 5.96M Jun/2026
Dianthus Therapeutics USD 463K 179K Mar/2026
Divis Laboratories Ltd INR 27.58B 730M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
IQVIA Holdings USD 4.37B 220M Jun/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Moderna USD 100M 289M Jun/2026
Organigram Holdings CAD 59.79M 3.74M Mar/2026
Organon & Co USD 1.56B 100M Jun/2026
Revvity USD 729.68M 18.68M Jun/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 217.51M 74.75M Dec/2025
Viatris USD 3.76B 240M Jun/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026
Zealand Pharma A/S 34M 34.92M Mar/2026